How Enveric Biosciences Is Prepping For Its First IND [Clinical Leader]
Friday, October 10, 2025 1 min read
Key Takeaway: Enveric Biosciences is preparing to submit its first Investigational New Drug (IND) application to the FDA for EB-003, a novel neuroplastogen. This therapy aims to provide a fast-acting, non-hallucinogenic treatment for conditions such as post-traumatic stress disorder, treatment-resistant depression, and generalized anxiety. The company previously opted out of a Phase 1 trial in Australia.
Price reaction · baseline $8.4564 (2025-10-09 close) · hit pre-market · 7 other ENVB headline(s) in the window, move may be shared
day 0 close
-11.3%
day 1
-8.4%
day 3 · peak
+27.7%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences is submitting its first IND to the FDA.
EB-003 is designed as a fast-acting and well-tolerated therapy.
The therapy targets significant mental health conditions like PTSD and depression.
Full Press Release Details
There’s a first time for everything, and now is the time for Enveric Biosciences to submit its first-ever IND to the FDA.
After forgoing a Phase 1 in Australia and deciding to out-license that asset, Enveric now finds itself facing its first IND submission. This time, they’re seeking the OK for EB-003, a novel neuroplastogen designed to be a fast-acting, well-tolerated, and non-hallucinogenic therapy for those with post-traumatic stress disorder (PTSD), treatment-resistant depression, and generalized anxiety.
Full Article >>
Frequently Asked Questions
What is the purpose of Enveric's IND submission?
The IND submission is for EB-003, aimed at treating PTSD, depression, and anxiety.
What conditions does EB-003 target?
EB-003 targets post-traumatic stress disorder, treatment-resistant depression, and anxiety.
Why did Enveric skip the Phase 1 trial in Australia?
Enveric decided to out-license the asset instead of proceeding with the Phase 1 trial.
What type of therapy is EB-003?
EB-003 is a novel neuroplastogen designed to be fast-acting and non-hallucinogenic.